New Study Finds Aspirin Treatment Ineffective for Chronic Rhinosinusitis with Nasal Polyps
A recent clinical trial reveals that aspirin therapy offers no significant benefit for patients with chronic rhinosinusitis with nasal polyps, especially those hypersensitive to NSAIDs, emphasizing the need for alternative treatment approaches.
Recent research from the University of Eastern Finland, in collaboration with the University of Helsinki and HUS Inflammation Center, has revealed that aspirin therapy does not significantly improve symptoms or quality of life for patients suffering from chronic rhinosinusitis with nasal polyps (CRSwNP), particularly in those hypersensitive to non-steroidal anti-inflammatory drugs (NSAIDs). The study was published in the journal Allergy and involves a comprehensive clinical trial involving 26 patients with NSAID-exacerbated respiratory disease (N-ERD), asthma, and severe CRSwNP.
The trial involved administering aspirin desensitization to these patients, then randomly assigning them to receive either daily aspirin or a placebo over an 11-month period. The results showed no notable difference in symptom severity, lung function, or the number of corticosteroid courses needed during flare-ups between the two groups. While some indications suggested that aspirin therapy might slightly reduce nasal polyps and improve nasal symptom-related quality of life, these effects were not statistically significant.
Furthermore, adverse effects were common, occurring in 56% of patients taking aspirin and 30% of those on placebo. Side effects ranged from worsening respiratory symptoms, increased bleeding tendencies, to abdominal discomfort. About 18% of patients in the aspirin group discontinued treatment due to side effects. The study concludes that aspirin therapy, despite being affordable, does not offer a reliable benefit for most patients with CRSwNP and hypersensitivity to NSAIDs, and identifying individuals who might benefit remains challenging.
This research highlights the importance of evidence-based treatments and suggests that current biologic medications, although effective, are often expensive. The findings aim to guide clinicians in making informed decisions about managing CRSwNP associated with NSAID hypersensitivity.
Source: https://medicalxpress.com/news/2025-09-aspirin-therapy-ineffective-chronic-rhinosinusitis.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Approach Reprograms Regulatory T Cells to Combat Cancer
Scientists have developed a pioneering method to reprogram immune cells within tumors, turning them from cancer protectors into active fighters, potentially enhancing cancer immunotherapy treatments.
FDA Approves Ajovy for Migraine Prevention in Children and Adolescents
The FDA has approved Ajovy, a CGRP antagonist, for preventing episodic migraines in children and adolescents aged 6 to 17, offering a new targeted treatment option for young patients. that can help reduce migraine attacks and improve quality of life.
How Sound Influences Brainwaves and Reshapes Neural Networks in Real Time
New research reveals how listening to sounds and music can actively induce real-time reorganization of brain networks, advancing our understanding of neural dynamics and connectivity.
Artificial Sweetener Sucralose May Reduce Effectiveness of Cancer Immunotherapy
Emerging research indicates that the artificial sweetener sucralose may reduce the effectiveness of cancer immunotherapy by altering gut microbiota and immune cell function. Learn what this means for cancer patients and their dietary choices.